United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and

Israel - English - Ministry of Health

taro international ltd, israel - sunitinib - hard capsule - sunitinib 12.5 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - English - Ministry of Health

taro international ltd, israel - sunitinib - hard capsule - sunitinib 25 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - English - Ministry of Health

taro international ltd, israel - sunitinib - hard capsule - sunitinib 37.5 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - English - Ministry of Health

taro international ltd, israel - sunitinib - hard capsule - sunitinib 50 mg - sunitinib - sunitinib taro is indicated for:• treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. • treatment of advanced renal cell carcinoma.• treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - English - Ministry of Health

teva israel ltd - sunitinib as base - capsules - sunitinib as base 12.5 mg - sunitinib - sunitinib teva is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib teva is indicated for the treatment of advanced renal cell carcinoma. treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - English - Ministry of Health

teva israel ltd - sunitinib as base - capsules - sunitinib as base 25 mg - sunitinib - sunitinib teva is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib teva is indicated for the treatment of advanced renal cell carcinoma. treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - English - Ministry of Health

teva israel ltd - sunitinib as base - capsules - sunitinib as base 37.5 mg - sunitinib - sunitinib teva is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib teva is indicated for the treatment of advanced renal cell carcinoma. treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Israel - English - Ministry of Health

teva israel ltd - sunitinib as base - capsules - sunitinib as base 50 mg - sunitinib - sunitinib teva is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sunitinib teva is indicated for the treatment of advanced renal cell carcinoma. treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - dasatinib - film-coated tablet - 100 milligram(s) - dasatinib